Literature DB >> 15126313

Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.

Richard F Harvey1, J Athene Lane, Liam J Murray, Ian M Harvey, Jenny L Donovan, Prakash Nair.   

Abstract

OBJECTIVES: To investigate the effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux.
DESIGN: Cross sectional study, followed by a randomised placebo controlled trial.
SETTING: Seven general practices in Bristol, England. PARTICIPANTS: 10,537 people, aged 20-59 years, with and without H pylori infection (determined by the (13)C-urea breath test). MAIN OUTCOME MEASURES: Prevalence of heartburn and gastro-oesophageal acid reflux at baseline and two years after treatment to eradicate H pylori infection.
RESULTS: At baseline, H pylori infection was associated with increased prevalence of heartburn (odds ratio 1.14, 95% confidence interval 1.05 to 1.23) but not reflux (1.05, 0.97 to 1.14). In participants with H pylori infection, active treatment had no effect on the overall prevalence of heartburn (0.99, 0.88 to 1.12) or reflux (1.04, 0.91 to 1.19) and did not improve pre-existing symptoms of heartburn or reflux.
CONCLUSIONS: H pylori infection is associated with a slightly increased prevalence of heartburn but not reflux. Treatment to eradicate H pylori has no net benefit in patients with heartburn or gastro-oesophageal reflux.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126313      PMCID: PMC421785          DOI: 10.1136/bmj.38082.626725.EE

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  29 in total

1.  Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus.

Authors:  R J Loffeld; B F Werdmuller; J G Kuster; G I Pérez-Pérez; M J Blaser; E J Kuipers
Journal:  Digestion       Date:  2000       Impact factor: 3.216

2.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

Authors:  J Labenz; A L Blum; E Bayerdörffer; A Meining; M Stolte; G Börsch
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

3.  Helicobacter pylori infection and chronic gastric acid hyposecretion.

Authors:  E M El-Omar; K Oien; A El-Nujumi; D Gillen; A Wirz; S Dahill; C Williams; J E Ardill; K E McColl
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

4.  A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection.

Authors:  J E Domínguez-Muñoz; A Leodolter; T Sauerbruch; P Malfertheiner
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

5.  Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.

Authors:  P Moayyedi; R Feltbower; J Brown; S Mason; J Mason; J Nathan; I D Richards; A C Dowell; A T Axon
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

6.  Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings.

Authors:  T Shirota; M Kusano; O Kawamura; T Horikoshi; M Mori; T Sekiguchi
Journal:  J Gastroenterol       Date:  1999-10       Impact factor: 7.527

7.  Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease.

Authors:  R V Varanasi; G T Fantry; K T Wilson
Journal:  Helicobacter       Date:  1998-09       Impact factor: 5.753

8.  Corpus gastritis is protective against reflux oesophagitis.

Authors:  H B El-Serag; A Sonnenberg; M M Jamal; J M Inadomi; L A Crooks; R M Feddersen
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

9.  High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.

Authors:  H Hamada; K Haruma; M Mihara; T Kamada; M Yoshihara; K Sumii; G Kajiyama; M Kawanishi
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

10.  Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis.

Authors:  B F Werdmuller; R J Loffeld
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

View more
  15 in total

1.  Eradicating H pylori.

Authors:  Brendan Delaney; Paul Moayyedi
Journal:  BMJ       Date:  2004-06-12

2.  Helicobacter pylori and gastro-oesophageal reflux disease: information underlying pathology is not given.

Authors:  Giovanni Cammarota; Giovanni B Gasbarrini
Journal:  BMJ       Date:  2004-08-14

3.  Helicobacter pylori and gastro-oesophageal reflux disease: important data were not presented.

Authors:  Ian L P Beales
Journal:  BMJ       Date:  2004-08-14

Review 4.  Dyspepsia and Helicobacter pylori.

Authors:  Rupal Shah
Journal:  BMJ       Date:  2007-01-06

5.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

6.  Diagnosis and Treatment of Helicobacter pylori.

Authors:  Mae F Go
Journal:  Curr Treat Options Gastroenterol       Date:  2005-04

Review 7.  Helicobacter pylori infection.

Authors:  Grigorios I Leontiadis; Paul Moayyedi; Alexander Charles Ford
Journal:  BMJ Clin Evid       Date:  2009-10-01

8.  Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial.

Authors:  J Athene Lane; Liam J Murray; Sian Noble; Matthias Egger; Ian M Harvey; Jenny L Donovan; Prakash Nair; Richard F Harvey
Journal:  BMJ       Date:  2006-01-20

9.  Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis.

Authors:  Wen-Ling Mou; Meng-Yao Feng; Li-Hua Hu
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

Review 10.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.